Peter V Spacciapoli Deceased7 Moulton Rd, Peabody, MA 01960

6528488, Mar 4, 2003

Jan 8, 1999

09/226666

Peter Spacciapoli - Newbury MA
David M. Rothstein - Lexington MA
Phillip M. Friden - Bedford MA

Demegen, Inc. - Pittsburgh PA

A61K 3808

514 14, 514 12, 514 13, 514 15, 514 16, 514 21

Methods for treating cystic fibrosis in a mammal that include administering to the mammal an effective amount of a histatin, a histatin fragment, or a histatin-related peptide are disclosed.

6531573, Mar 11, 2003

Dec 18, 1997

08/993235

Frank G. Oppenheim - Chestnut Hill MA
Tao Xu - Newton MA
F. Donald Roberts - Dover MA
Peter Spacciapoli - Newbury MA
Phillip M. Friden - Bedford MA

Trustees of Boston University - Watertown MA
Periodontix, Inc. - Boston MA

A61K 3800

530326, 530327, 514 13, 514 14

Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent; and R23 is Gly or is absent; and where Gln cannot simultaneously occupy positions R5, R6, R12, and R13 of the amino acid sequence, as well as pharmaceutical compositions containing these peptides and methods for treating fuingal and bacterial infections using these peptides, are disclosed.

5912230, Jun 15, 1999

Mar 11, 1998

8/973559

Frank G. Oppenheim - Chestnut Hill MA
Tao Xu - Newton MA
F. Donald Roberts - Dover MA
Peter Spacciapoli - Newbury MA
Phillip M. Friden - Bedford MA

Periodontix, Inc. - Watertown MA
Trustees of Boston University - Boston MA

A61K 3810
A61K 3808
C07K 706
C07K 708

514 12

Histatin-based peptides representing defined portions of the amino acid sequences of naturally occurring human histatins and methods for treatment of fungal or bacterial infection are described. These histatin-based peptides represent the active anti-fungal and anti-bacterial region of naturally occurring human histatins.

5885965, Mar 23, 1999

Mar 12, 1998

8/973563

Frank G. Oppenheim - Chestnut Hill MA
Tao Xu - Newton MA
F. Donald Roberts - Dover MA
Peter Spacciapoli - Newbury MA
Phillip M. Friden - Bedford MA

Periodontix, Inc. - Watertown MA
Trustees of Boston University - Boston MA

A61K 3808
A61K 3810
C07K 706
C07K 708

514 12

D-amino acid histatins and histatin-based peptides and methods for treatment of fungal or bacterial infection are described. These D-amino acid histatins and histatin-based peptides are longer-acting anti-fungal or anti-bacterial agents than their L-enantiomeric analogues.

6153210, Nov 28, 2000

Aug 14, 1997

8/911413

F. Donald Roberts - Dover MA
Phillip M. Friden - Bedford MA
Peter Spacciapoli - Newbury MA
Eric Nelson - Waltham MA

Periodontix, Inc. - Watertown MA

A61K 3338
A61K 970
A61K 31765
A61L 1503

424411

Periodontal disease can be treated by the administration of metal ions, preferably silver ions, to the site where the microorganisms that cause this disease reside. Administration can be to periodontal pockets or adjacent to exposed tooth roots or alveolar bone during periodontal surgical procedures. The metal ions can be administered in polymeric microparticles, deformable films or microparticles embedded within deformable films. The metal ions are particularly microbiocidal to the bacterial pathogens that are the causative agents of periodontal disease.

5646119, Jul 8, 1997

Jun 7, 1995

8/485273

Frank G. Oppenheim - Chestnut Hill MA
Tao Xu - Newton MA
Peter Spacciapoli - Newbury MA

Periodontix, Inc. - DE
The Trustees of Boston University - MA

A61K 3808
A61K 3810
C07K 706
C07K 708

514 12

D-amino acid histatins and histatin-based peptides histatins and methods for treatment of fungal or bacterial infection are described. These D-amino acid histatins and histatin-based peptides are longer-acting anti-fungal or anti-bacterial agents than their L-enantiomeric analogues.